Walter M. Stadler to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Walter M. Stadler has written about Dose-Response Relationship, Drug.
Connection Strength
0.570
-
Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
Score: 0.171
-
Effective therapy for metastatic renal cancer, whither to now. J Clin Oncol. 2009 Aug 01; 27(22):3573-4.
Score: 0.062
-
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer. 2008 Mar; 6(1):21-4.
Score: 0.057
-
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
Score: 0.044
-
Drug dosing in cancer patients with decreased kidney function: A practical approach. Cancer Treat Rev. 2021 Feb; 93:102139.
Score: 0.035
-
In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer. Urology. 1999 Sep; 54(3):573-7.
Score: 0.032
-
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
Score: 0.029
-
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016 Mar; 17(3):378-388.
Score: 0.025
-
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan; 77(1):155-62.
Score: 0.024
-
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20; 29(30):4022-8.
Score: 0.018
-
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):679-86.
Score: 0.017
-
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
Score: 0.012
-
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):678-89.
Score: 0.011
-
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
Score: 0.011
-
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 01; 22(5):909-18.
Score: 0.011
-
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
Score: 0.010